research

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Seeking Alpha

2 min read

0 likes

⚡ Quantum Brief

Cullinan Therapeutics highlighted 2026 as a pivotal year with key catalysts for its oncology pipeline, particularly its T-cell engagers CLN-978 and CLN-049, during Citi’s Virtual Oncology Leadership Summit. CEO Nadim Ahmed emphasized the company’s strategic focus on advancing these high-priority assets, signaling potential breakthroughs in targeted cancer therapies through modular protein engineering. Chief Medical Officer Jeffrey Jones joined the discussion, underscoring clinical progress and regulatory milestones expected in 2026, though specific trial details were not disclosed in the transcript. The presentation addressed investor questions via a live Q&A, with analysts probing pipeline prioritization and development timelines, reflecting strong market interest in Cullinan’s innovative approaches. Citi’s biotech analyst Samantha Semenkow moderated the session, facilitating dialogue on Cullinan’s broader oncology strategy and its positioning in the competitive immuno-oncology landscape.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts158.5K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Cullinan Therapeutics, Inc. (CGEM) Citi's 2026 Virtual Oncology Leadership Summit February 19, 2026 10:00 AM EST Company Participants Nadim Ahmed - President, CEO & DirectorJeffrey Jones - Chief Medical Officer Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha SemenkowCitigroup Inc., Research Division Good morning, and thank you for joining our session of Citi's Virtual Oncology Leadership Summit. I'm Sam Semenkow, one of the senior biotech analysts here at Citi. And it's my pleasure today to be hosting Cullinan Therapeutics' CEO, Nadim Ahmed; and CFO (sic) [ CMO ], Jeff Jones. Nadim, Jeff, thank you very much for joining us today. Nadim AhmedPresident, CEO & Director Great to be here, Sam. Jeffrey JonesChief Medical Officer Thank you. Samantha SemenkowCitigroup Inc., Research Division And so for those listening live, if you have any questions during the session, please feel free to e-mail them to me directly at samantha.semenkow@citi.com or you can put them into the portal, and those go to my e-mail as well, and I'd be happy to ask those questions on your behalf. Question-and-Answer Session Samantha SemenkowCitigroup Inc., Research Division So I think we can just get started then. So Nadim, maybe you can kick us off a little bit and talk about the evolution of Cullinan's oncology pipeline, a little bit about what assets you've prioritized recently, the company's overall strategy when it comes to developing assets for oncology in particular. Nadim AhmedPresident, CEO & Director Sure. Happy to do that, Sam. Look, the first thing I'd say is 2026 is a very exciting year for Cullinan Therapeutics. We've got multiple catalysts across our whole program and pipeline and especially for our 2 high-priority T cell engagers, CLN-978 and CLN-049. If I may divert slightly away from oncology for a second

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.